A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.
about
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancerNew challenges in perioperative management of pancreatic cancerUse of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinomaAssociation of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy.The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth.Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapyPharmGKB summary: gemcitabine pathwayA randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trialPrognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.Adenocarcinoma of the pancreasIn Vitro and In Vivo Comparison of Gemcitabine and the Gemcitabine Analog 1-(2'-deoxy-2'-fluoroarabinofuranosyl) Cytosine (FAC) in Human Orthotopic and Genetically Modified Mouse Pancreatic Cancer Models.miR-211 regulates the expression of RRM2 in tumoral metastasis and recurrence in colorectal cancer patients with a k-ras gene mutation.
P2860
Q28075540-630EE818-BC75-48AA-A615-194967CFE3CBQ28082422-5CD265E9-73B6-40BC-8D39-C30CB8D6B714Q33751227-EED7C7E1-07ED-42EF-919D-D302D63EFD36Q33874242-CF183CCB-4E23-4FD7-80D8-7D428979F1AEQ34041619-10F1B482-786F-4B76-9BE8-53BB29069DC0Q34283650-FDAE5195-3A13-4546-867F-A1D274056FDCQ34435450-16BC97AD-05D7-44EC-8B91-6C2C57A015D0Q36131174-DD721869-D2D1-4EF8-9DE0-E2E26BBC9CB5Q36762499-843E9211-BDC9-475D-B2D3-08FD9E001FDBQ38274043-BEE41457-23C0-4BF5-8F5F-35F64E587BE1Q47109380-65EAA231-18D1-4562-9905-4E6529089465Q54983378-67D60536-6EB1-4BEF-8433-EEF0327C643C
P2860
A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.
@en
A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.
@nl
type
label
A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.
@en
A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.
@nl
prefLabel
A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.
@en
A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.
@nl
P2093
P2860
P1433
P1476
A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.
@en
P2093
Christina H Wei
David A Elashoff
James J Farrell
O Joe Hines
Timothy R Donahue
Tristan R Gorgan
P2860
P304
P356
10.1097/MPA.0B013E3182A23AE4
P577
2013-11-01T00:00:00Z